(NASDAQ: CRON) Cronos Group's forecast annual earnings growth rate of -34.53% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 42.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.94%.
Cronos Group's earnings in 2025 is $49,443,000.On average, 1 Wall Street analyst forecast CRON's earnings for 2025 to be -$11,562,571, with the lowest CRON earnings forecast at -$11,562,571, and the highest CRON earnings forecast at -$11,562,571.
In 2026, CRON is forecast to generate $23,125,141 in earnings, with the lowest earnings forecast at $23,125,141 and the highest earnings forecast at $23,125,141.